ZEVTERA® (ceftobiprole medocaril, IV) is a semi-synthetic, pro-drug form of a cephalosporin antibiotic. ZEVTERA exerts its bactericidal activity through binding to penicillin-binding proteins (PBP) in susceptible bacterial species. ZEVTERA is a broad-spectrum antibiotic with activity against a wide range of Gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), and Gram-negative bacteria, including susceptible Pseudomonas spp.
Correvio commercializes ZEVTERA under agreement with Basilea Pharmaceutica in Austria, France, Germany, Italy, Spain, Switzerland and the UK.
The current ZEVTERA Summary of Product Characteristics in the UK can be found here, in Austria here, in Germany here, in France here, in Italy here. and in Switzerland here.